<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">APROBARBITAL</span><br/>(a-pro-bar'bi-tol)<br/><span class="topboxtradename">Alurate<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">anxiolytic, sedative-hypnotic</span>; <span class="classification">barbiturate</span><br/><b>Prototype: </b>Secobarbital<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>40 mg/5 mL elixir</p>
<h1><a name="action">Actions</a></h1>
<p>Intermediate-acting barbiturate. These agents depress the sensory cortex, decrease motor activity, alter cerebellar function,
         and produce drowsiness, sedation, and hypnosis. Barbiturates have little analgesic action at subanesthetic doses and may increase
         the reaction to painful stimuli. All barbiturates exhibit anticonvulsant activity in anesthetic doses.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Barbiturates can produce all levels of CNS mood alteration, from excitation to mild sedation, hypnosis, and deep coma. Barbiturates
         are respiratory depressants; the degree of respiratory depression is dose dependent. With hypnotic doses, respiratory depression
         is similar to that which occurs during physiologic sleep.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Indicated for routine sedation and as a hypnotic in the short-term treatment of insomnia for up to 2 wk. Barbiturates seem
         to lose their efficacy for sleep induction and maintenance after this period of time.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Barbiturate hypersensitivity; history of manifest or latent porphyria; impaired liver function; impaired renal function; severe
         respiratory distress, respiratory disease where dyspnea, obstruction, or cor pulmonale is present; previous addiction to the
         sedative-hypnotic group; acute or chronic pain. Safety during pregnancy (category D), lactation, or in children is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Older adults or debilitated patients, presence of fever, hyperthyroidism, diabetes mellitus, severe anemia, debility, severely
         impaired liver function, pulmonary or cardiac disease, status asthmaticus, shock, uremia, borderline hypoadrenal function.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Sedative</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 40 mg t.i.d.<br/><br/><span class="indicationtitle">Hypnotic</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 40160 mg<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Determine if lower initial dose should be used in patient with impaired renal or hepatic function.</li>
<li>Determine if an increase in dosage is needed for patient on dialysis.</li>
<li>
            				Note: Not to be used on prolonged basis; demonstrated effectiveness is only 2 wk.
            			
         </li>
<li>Store away from heat and direct light in airtight container at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Somnolence</span>, agitation, confusion, hyperkinesia, ataxia, vertigo, CNS depression, nightmares, lethargy, <span class="speceff-common">residual sedation (hangover effect)</span>, paradoxical excitement, nervousness, psychiatric disturbance, hallucinations, insomnia, anxiety, dizziness, thinking abnormalities,
      delirium and stupor with excessive amounts. <span class="typehead">CV:</span> Bradycardia, <span class="speceff-life">circulatory collapse</span>, hypotension, syncope. <span class="typehead">GI:</span> Nausea, vomiting, constipation, diarrhea, epigastric pain. <span class="typehead">Hematologic:</span>
<span class="speceff-life">Agranulocytosis</span> (rare). <span class="typehead">Respiratory:</span> Hypoventilation, <span class="speceff-life">apnea, respiratory depression, laryngospasm</span>, bronchospasm. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>
<span class="classification">barbiturates</span> may cause a false-positive <span class="alt">phentolamine test</span> and decrease serum bilirubin concentrations.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">cns depressants</span>, <b>alcohol,</b>
<span class="classification">sedatives</span> compound CNS depression; <span class="classification">mao inhibitors</span> cause excessive CNS depression; <span class="classification">anticonvulsants</span>, <b>rifampin,</b>
<b>phenmetrazine</b> may decrease effects of aprobarbital. <span class="typehead">Herbal:</span>
<b>Kava-kava,</b>
<b>valerian</b> may potentiate sedation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed from GI tract. <span class="typehead">Onset:</span> 4560 min. <span class="typehead">Duration:</span> 3 h. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in the liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 1440 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for severe drowsiness, severe confusion, severe weakness, shortness of breath, slow or troubled breathing, slurred
            speech, staggering gait, and bradycardia.
         </li>
<li>Lab tests: Monitor hematologic studies for blood dyscrasia; monitor liver function studies with continuous or prolonged use.</li>
<li>Monitor older adults for paradoxical response (i.e., irritability, marked excitement, depression, and confusion).</li>
<li>Monitor phenytoin and barbiturate blood levels frequently if given concurrently because the effect of barbiturates on metabolism
            is unpredictable.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not increase the dose of the drug without consulting a physician.</li>
<li>Avoid use of alcohol or other CNS depressants.</li>
<li>Do not drive or engage in potentially hazardous tasks until response to drug is known.</li>
<li>Notify physician if any of the following occurs: fever, sore throat, mouth sores, easy bruising or bleeding, nosebleed, or
            petechiae.
         </li>
<li>Do not discontinue use of medication abruptly; physician may want to taper dosage to avoid possibility of withdrawal symptoms.</li>
<li>Check with physician for suspected psychological or physical dependence.</li>
<li>Increase vitamin Dfortified foods (e.g., milk products); drug increases vitamin D metabolism, leading to subtherapeutic
            levels and possible onset of osteomalacia or rickets.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>